What are the medication options for Cluster B Borderline Personality Disorder (BPD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Selective serotonin reuptake inhibitors (SSRIs) are the most appropriate medication option for Cluster B borderline personality disorder, as they reduce suicidal ideation and suicide attempts in nondepressed adults with this condition. When considering medication for Cluster B personality disorders, it's crucial to weigh the benefits and risks, particularly in terms of morbidity, mortality, and quality of life. According to the study by 1, SSRIs are not only effective in reducing suicidal ideation and attempts but also safe in children and adolescents, with low lethality.

Key considerations for medication management include:

  • Monitoring for new suicidal ideation or akathisia, as SSRIs may have a disinhibiting effect in some patients
  • Avoiding tricyclic antidepressants as a first-line treatment due to their potential lethality and lack of proven efficacy in children or adolescents
  • Prescribing other medications, such as benzodiazepines and phenobarbital, with caution due to their potential to increase disinhibition or impulsivity
  • Ensuring careful monitoring by a third party and immediate reporting of any behavioral changes or side effects

In terms of specific medication options, SSRIs like fluoxetine, sertraline, or escitalopram may be prescribed to address mood symptoms and impulsivity. However, the primary goal of medication treatment should be to reduce symptoms that impact morbidity, mortality, and quality of life, rather than solely focusing on personality traits. As such, medication should be part of a comprehensive treatment plan that includes psychotherapy, such as dialectical behavior therapy (DBT), to address the core symptoms and traits of Cluster B personality disorders.

From the Research

Cluster B Borderline Personality Disorder Medications Options

  • The following medications have been studied for the treatment of borderline personality disorder:
    • Selective serotonin reuptake inhibitors (SSRIs) such as fluvoxamine, fluoxetine, sertraline, paroxetine, and citalopram 2, 3, 4, 5
    • Omega-3 fatty acids 6
    • Second-generation antipsychotics 6
    • Mood stabilizers 6, 4
  • SSRIs have been shown to be effective in reducing symptoms of borderline personality disorder, including affective instability and impulsivity 2, 3, 4
  • The choice of medication may depend on the specific symptoms and needs of the patient, as well as the presence of any co-occurring conditions 6, 4
  • It is essential to note that medication should be used in conjunction with psychotherapy and other therapeutic interventions for optimal treatment of borderline personality disorder 6

Specific Medications

  • Fluvoxamine has been shown to be effective in reducing rapid mood shifts in female patients with borderline personality disorder 2
  • Fluoxetine has been shown to be effective in reducing symptoms of borderline personality disorder, including depression and impulsivity 3
  • Sertraline and citalopram are suggested as first-choice medications for the treatment of older adults with borderline personality disorder, due to their efficacy and safety profile 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Fluoxetine in the treatment of borderline personality disorder].

Actas luso-espanolas de neurologia, psiquiatria y ciencias afines, 1997

Research

Selective Serotonin Reuptake-Inhibitors for Symptom-Based Treatment of Borderline Personality Disorders in Older Adults: An International Delphi Study.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2021

Research

Selective serotonin-reuptake inhibitors: an update.

Harvard review of psychiatry, 1999

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.